These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19109335)

  • 1. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
    Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Tsiouris I; Roilides E; Walsh TJ
    J Antimicrob Chemother; 2009 Feb; 63(2):343-8. PubMed ID: 19109335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.
    Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Tsiouris I; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2196-204. PubMed ID: 18299413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S; Tunger A; Cilli F
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP; Warner M; Livermore DM
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; Climent A; Royo G
    Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.
    Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Walsh TJ; Roilides E
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5923-9. PubMed ID: 21911564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
    Li X; Mariano N; Rahal JJ; Urban CM; Drlica K
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4460-2. PubMed ID: 15504883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro.
    Heller I; Leitner S; Dierich MP; Lass-Flörl C
    Int J Antimicrob Agents; 2004 Oct; 24(4):401-4. PubMed ID: 15380269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].
    Yalçin B; Kalkanci A; Gürelik F; Fidan I; Kustimur S; Ozdek S
    Mikrobiyol Bul; 2010 Jan; 44(1):65-70. PubMed ID: 20455400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
    Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fluoroquinolones against pathogenic oral bacteria.
    Núñez Otero V; Limeres Posse J; Carmona IT; Diz Dios P
    Mini Rev Med Chem; 2009 Sep; 9(10):1147-58. PubMed ID: 19534690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
    Heinemann B; Wisplinghoff H; Edmond M; Seifert H
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.